CHICAGO — The annual assembly of the American Society of Medical Oncology is again in full pressure right here, with plenaries and poster classes as packed as earlier than the pandemic.
The massive information from the primary few days is that the AstraZeneca drug Tagrisso cuts deaths in half when given to non-small cell lung most cancers sufferers with an EGFR mutation after surgical procedure. That implies that over 5 years, yet another affected person out of each 10 would nonetheless be alive.
Hopeful outcomes had been offered for sufferers with glioma, a sort of mind most cancers that tends to strike individuals in center age. The drug vorasidenib, made by Servier, decreased the expansion of grade 2 glioma tumors by 61%, that means that it slowed the time it took tumors to be labeled as progressing to 27.7 months, slightly than 11.1 months for many who took a placebo.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED